SEC Tracker
Get the app
ANIP · XBRL financial data

Ani Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ANIP's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers132132*137138148191*197211228247*237266
Research and development1110*1171017*11171212*1115
Selling, general and administrative4244*48537970*77827783*7492
Operating income (loss)187*205(21)(4)*26143635*3940
Interest expense88*7779*8888*87
Other income (expense)(0)(0)*(0)(0)(3)(1)*02(1)1*(1)(0)
Income tax expense (benefit)2(0)*70(7)(3)*4274*1112
Net income (loss)101*18(2)(24)(10)*1692727*2925
Earnings per share, basic USD per share0.460.06*0.84(0.14)(1.27)—0.700.371.191.33*1.311.09
Earnings per share, diluted USD per share0.450.06*0.82(0.14)(1.27)—0.690.361.131.17*1.281.05
Weighted average shares, basic millions of shares1919*19191919*20202021*2121
Weighted average shares, diluted millions of shares1919*19191919*20202123*2222

Balance sheet

CSV

Fiscal quarters (ANIP's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents193221229240145145150218263286311360
Accounts receivable179162172166196222220226253281255274
Inventory107111114125148137137138146143143143
Total current assets497520541555521528536603698753747825
Property and equipment, net444549525757585964626773
Right-of-use asset————————5———
Goodwill282828286060616162626262
Total assets8909049159211,2871,2841,2921,3431,4081,4401,4221,494
Accounts payable343749496146535570637074
Accrued liabilities56771814121514171417
Current portion of long-term debt111179111315171921
Total current liabilities134145137140190194202237271278240284
Long-term debt285285285284313309305301298292286280
Lease liability, non-current—4———4———9——
Total liabilities435447438440857855849881902900860897
Retained earnings (accumulated deficit)(81)(80)(62)(65)(90)(100)(85)(77)(51)(23)631
Total stockholders' equity430433452456406404419437506541562597
Total liabilities and equity8909049159211,2871,2841,2921,3431,4081,4401,4221,494
Common shares outstanding (cover page) millions of shares—————21———22——

Cash flows

CSV

Fiscal quarters (ANIP's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)101*18(2)(24)(10)*1692727*2925
Stock-based compensation5*6*78*7*7*910*10*10*1011*
Net cash from operating activities32*45*1817*12*16*3576*44*30*5857*
Purchases of property and equipment2*2*54*5*2*24*6*1*63*
Net cash from investing activities(5)*(5)*9(4)*(399)*(11)*(20)(7)*(6)*(1)*(11)(3)*
Proceeds from issuing common stock0*0*——0*0*———year only——
Share repurchases1*0*91*1*0*101*1*1*201*
Dividends paid0*0*00*0*0*00*0*0*00*
Net cash from financing activities4*(12)*(20)(1)*291*(5)*(10)(2)*6*(5)*(22)(5)*
Net change in cash31*28*712*(95)*(0)*568*45*23*2649*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Ani Pharmaceuticals36026657*not reported— 10-QJun 30, 2026
Celldex Therapeutics470(57)*78.5M12.5 quarters 10-QJun 30, 2026
Travere Therapeutics12422598*96.0M— 10-QSep 30, 2026
Innoviva57012052*72.2M— 10-QJun 30, 2026
Adaptive Biotechnologies17072(6.4)*159.6M53.8 quarters 10-QJun 30, 2026
Arrowhead Pharmaceuticals5575(177)*141.3M9.0 quarters 10-QJun 30, 2026
Mannkind53109(18)*321.5M6.0 quarters 10-QJun 30, 2026
Schrodinger28859(34)*not reported12.1 quarters 10-QJun 30, 2026
Spyre Therapeutics83not reported(77)*95.0M15.7 quarters 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.